Dr Jason Brown
Jason co-founded Ubiquigent in 2009 in collaboration with the University of Dundee, the Medical Research Council and a US biotech. Ubiquigent’s mission is to support and enable client ubiquitin system targeted drug discovery through the identification and characterisation of novel compounds across multiple therapeutic areas. The company is a provider of such collaborations and services worldwide to both commercial pharmaceutical and biotechnology companies as well as academic groups. Before starting Ubiquigent he was part of a biotech investment and operations group and involved in supporting molecular diagnostics, kinase drug discovery and various other drug discovery-focused service companies, along with evaluating investment opportunities. Prior to this he built and ran a kinase-focused assay development and drug discovery service facility for Upstate Biotechnology, a leading provider of cell signalling research products and services. Jason received his MPhil and DPhil from the University of Cambridge in association with Parke-Davis/Warner-Lambert (Pfizer), during which he identified a voltage-dependent calcium channel subunit as the novel molecular target of the blockbuster epilepsy and neuropathic pain drugs Neurontin and Lyrica. After his DPhil Jason worked in and subsequently ran an assay development group for Parke-Davis.
Tiffany Scharschmidt M.D.
Tiffany Scharschmidt is an Assistant Professor in the Department of Dermatology at the University of California, San Francisco. She received her M.D. from UCSF and completed her scientific training in the labs of Julia Segre, Michael Fischbach and Michael Rosenblum where she acquired expertise in both microbiology and immunology. Her work has demonstrated that adaptive immune tolerance to commensal skin bacteria is preferentially established in neonatal life in conjunction with coordinated recruitment of regulatory T cells into neonatal skin by commensals and hair follicles. Her lab investigates host-directed and microbe-directed mechanisms that promote healthy dialogue between skin bacteria and the adaptive immune system, with a focus on early life events. Dr. Scharschmidt is the recipient of an NIH Director’s New Innovator Award, a Burroughs Wellcome Career Award for Medical Scientists, a Doris Duke Clinician-Scientist Development Award and the American Academy of Dermatology’s Young Investigator of the Year Award.
